Buprenorphine 54 411

In the heart of the town Taormina, Hotel Metropole (http://www.charmingitaly.com/hotel/hotel-metropole) offers a sparkling atmosphere, aperitifs, exhibitions...

the subutex i have are white round and say 54 411 on them, i have taken suboxone for a year, although im glad to not be using anymore i hate suboxone, my quality of life sux, im sick all the time excruciating headaches. i just feel run down, rapid heart beat, severe weight gain. i used to run 3 miles a day, and now i dont run at all, dont enjoy it, relations with my husband have went down the ...Extensive evidence has established the safety and effectiveness of medications to treat OUD. Specifically, buprenorphine is associated with reductions in the risk of opioid use, 5 – 7 hospital-based care, 8, 9 mortality, 10 and treatment dropout. 5 – 8 Though retention rates are low, 11 studies suggest that the benefits of buprenorphine …Nov 24, 2020 · Buprenorphine is a sublingually and transdermally available, semisynthetic opioid analgesic, which is used as an analgesic and for management of opioid dependence. Therapy with buprenorphine is associated with mild and transient serum enzyme elevations, and with moderate-to-severe clinically apparent liver injury when abused by intravenous administration or the sublingual formations. QUICK START GUIDE. Specifically discuss safety concerns: Understand that discontinuing buprenorphine increases risk of overdose death upon return to illicit opioid use. Know that use of alcohol or benzodiazepines with buprenorphine increases the risk of overdose and death. Understand the importance of informing providers if they become pregnant.Mar 1, 2018 · Buprenorphine has high affinity for but low intrinsic activity at the μ opioid receptors, and will displace morphine, methadone, and other full opioid agonists from those receptors. Full agonists ... Meta-analysis was performed using the R, version 3.2.2, Metafor package, version 1.9-7. Results: The meta-analysis revealed that buprenorphine has a beneficial effect on pain intensity overall, with a small mean effect size in patients with comorbid chronic pain and OUD and a moderate- to large-sized effect in chronic pain patients …

The following drug pill images match your search criteria. Search Results. Search Again. Results 1 - 5 of 5 for " 54 375". 54 375. Buprenorphine Hydrochloride and Naloxone Hydrochloride (Sublingual) Strength. 8 mg (base) / 2 mg (base) Imprint.Subutex (Buprenorphine) is an opioid drug that is structurally similar to morphine. It is most often used for either pain control or opioid dependence/withdrawal. The drug does have some unusual characteristics that vary from many of the other drugs in the opioid class. While most drugs in the class tend to be metabolized and excreted from the ...Buprenorphine is a Schedule III opioid with unique pharmacodynamic and pharmacokinetic properties that contribute to effective analgesia and fewer safety risks than other opioids. This review article focuses on the buccal film formulation, which is preferable to other buprenorphine formulations on the basis of bioavailability, safety and efficacy.Subutex is a sublingual tablet used for opioid addiction. Suboxone is a formulation that contains buprenorphine and naloxone in 4:1 ratio. Naloxone, an opioid antagonist, was added to deter injection of dissolved pills, thus reducing abuse liability and the potential for diversion. ... 1997; 54 (8):713-20. [Google Scholar] 22.Email or text this coupon to yourself. $ 54.60. Retail price: $ 778.28. Show this coupon at the pharmacy. BIN. 015995.

Belbuca (buprenorphine) is typically prescribed by a pain management specialist. It's a buccal film, which means that the film is placed on the inside the cheek to dissolve. This medication is typically taken twice a day. The most common side effects are nausea and constipation. Belbuca (buprenorphine) isn't available as a lower-cost generic ...This medication contains 2 medicines: buprenorphine and naloxone.It is used to treat opioid use disorder. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists ...Buprenorphine belongs to a class of medications called opiate partial agonists. Buprenex works by changing the way the body senses pain.acute pain. This medication guide provides information about the Buprenex brand of buprenorphine injection. Sublocade is another brand of buprenorphine injection used to treat opioid addiction. Buprenex side ... INTRODUCTION. Buprenorphine, an oripavine derivative, is used clinically for pain management [21,74].This opioid analgesic, which was the focus of many clinical trials for the treatment of opioid dependency [32,47,49,50,59], even in opiate addicts with a history of cocaine co-abuse [72,85,86], has recently been approved for the treatment of opioid dependency [].

Indiana school employee salaries.

Sublingual Film (Suboxone [also generic], buprenorphine and naloxone, 2002) 2-8/.05-2 mg daily (first day) - 24/6mg daily: ... (6.54 ng/ml after four 300mg injections; 3.21 ng/ml after four 100mg injections) . Higher blood level could be an advantage in terms of achieving full occupancy and blockade of opioid receptors.Suboxone and Subutex, both of which were approved by the FDA in 2002, are drugs developed for the treatment of opiate addiction. Prior to 2000 when the Drug Addiction Treatment Act was passed, the primary medication to treat opiate addictions was methadone.In 2000, however, burprenorphine was approved in the law, and it could be prescribed by physicians who have been trained and certified by ...Descriptions. Buprenorphine injection is used to relieve moderate to severe pain. It is also used in patients who have received treatment with an oral form of buprenorphine that is placed under the tongue or inside the cheek for 7 days, followed by an adjustment in the dose for at least 7 days. Buprenorphine belongs to the group of …Descriptions. Buprenorphine injection is used to relieve moderate to severe pain. It is also used in patients who have received treatment with an oral form of buprenorphine that is placed under the tongue or inside the cheek for 7 days, followed by an adjustment in the dose for at least 7 days. Buprenorphine belongs to the group of medicines ...Find practitioners authorized to treat opioid dependency with buprenorphine by state. Select a state from the map or use the dropdown lists to view practitioners by city, state or zip code who previously held a DATA-2000 waiver to prescribe buprenorphine for the treatment of opioid use disorder (OUD).Buprenorphine patch preparations for twice weekly or weekly use are available with a range of transdermal drug delivery rates (5, 10, 20, 35, 52.5, 70 μg/hour). NICE suggests that a transdermal buprenorphine patch of 20 μg/hour equates to approximately 30 mg of oral morphine daily . Buprenorphine via either the transdermal or injectable route ...

There is general agreement across studies regarding buprenorphine induction and maintenance dose schedules. The clinical effects of buprenorphine and buprenorphine/naloxone are similar and most patients can be treated initially with and maintained on a daily buprenorphine/naloxone dose of 4:1-24:6 mg. Dosing is possible on a less-than-daily ...Today, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), announced the …This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process. Publication ID. SMA15-4442. Publication Date. August 2015.Emergency departments (EDs) administer lifesaving interventions all day every day and all night every night. In addition to rapidly resuscitating and stabilizing patients with acute illness and injury, emergency physicians are charged with identifying the appropriate level and type of care within the health care system — from intensive care ...Meta-analysis was performed using the R, version 3.2.2, Metafor package, version 1.9-7. Results: The meta-analysis revealed that buprenorphine has a beneficial effect on pain intensity overall, with a small mean effect size in patients with comorbid chronic pain and OUD and a moderate- to large-sized effect in chronic pain patients …People with opioid addiction often need to take buprenorphine daily for months to years to overcome addiction to the opioid they are trying to quit – whether it’s …The recommended administration of extended-release buprenorphine (BUP-ER) to treat opioid use disorder is 300 mg/month for two months followed by 100 mg/month after stabilization on transmucosal buprenorphine for ≥7 days. However, little is known about real-world use. Researchers performed a population-based cohort study characterizing BUP-ER ...Administer buprenorphine sublingual tablets sublingually as a single daily dose. (Strongly consider prescribing naloxone at the time buprenorphine sublingual tablets is initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose ()To avoid precipitating withdrawal, induction with buprenorphine sublingual ...The average blood level observed in the month after the first 300mg injection (2.19 ng/ml) was comparable to a level achieved between 12mg/day (1.71) and 24mg/day (2.91) of daily sublingual buprenorphine, although the steady state values after 4 monthly injections were considerably higher (6.54 ng/ml after four 300mg injections; 3.21 ng/ml ...Buprenorphine is a partial agonist acting at the mu‐opioid receptor with high receptor affinity. In an opioid‐dependent person, buprenorphine can displace opioid agonists of lower receptor affinity (e.g. heroin, methadone) from the receptors, without full activation (partial agonism), leading to a 'precipitated' opioid withdrawal [3, 4].

Buprenorphine is a Schedule III opioid analgesic with unique pharmacodynamic and pharmacokinetic properties that may be preferable to those of Schedule II full μ-opioid receptor agonists. The structure of buprenorphine allows for multimechanistic interactions with opioid receptors μ, δ, κ, and opioid receptor-like 1.

Buprenorphine has a quick onset of 30-60 minutes when it is administered sublingually and 5-15 minutes with IV administration . The usual dose of buprenorphine ranges from 2 to 32 milligram per day (mg/d) and the maximum effect occurs the dose between 16 and 32 mg/d . It provides effective analgesia at low to moderate doses and is 30 times more ...nausea, vomiting, constipation; headache, back pain; fast or pounding heartbeats, increased sweating; or. sleep problems ( insomnia ). This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.Results 1 - 7 of 7 for " 54 411". 1 / 4. 54 411. Buprenorphine Hydrochloride (Sublingual) Strength. 8 mg (base) Imprint. 54 411. Color.Buprenorphine, a controlled substance sold under the brand names Subutex and Suboxone, is a medication to treat opioid use disorder. Research shows it halves the risk of overdose and doubles ...Buprenorphine has moderate influence on the ability to drive and use machines. Buprenorphine may cause drowsiness, dizziness or impaired thinking especially during treatment induction and dose adjustment. If taken together with alcohol or central nervous system depressants, the effect is likely to be more pronounced (see section 4.4. and 4.5).Extensive evidence has established the safety and effectiveness of medications to treat OUD. Specifically, buprenorphine is associated with reductions in the risk of opioid use, 5 – 7 hospital-based care, 8, 9 mortality, 10 and treatment dropout. 5 – 8 Though retention rates are low, 11 studies suggest that the benefits of buprenorphine …Pill Identifier results for "411". Search by imprint, shape, color or drug name. Skip to main content. ... Buprenorphine Hydrochloride (Sublingual) Strength 8 mg (base) Imprint 54 411 Color White Shape Round View details. 1 / 5 Loading. 241 1 WATSON. Previous Next. Lorazepam Strength 1 mg Imprint 241 1 WATSON ColorReceptor inhibition is likely dependent on the dose of buprenorphine or concentration of buprenorphine at the receptor. 49 – 54 However, the buprenorphine doses provided by the BTDS in the US are relatively low. For example, the systemic buprenorphine-delivery rate from the BTDS averages 5, 7.5, 10, 15, and 20 μg/hour …Introduction. The availability of buprenorphine for opioid pharmacotherapy is the most significant event in addiction medicine since the introduction of methadone maintenance in the 1960s.1,2 Its true clinical significance was not in having another safe and effective medication to treating Opioid Use Disorder (OUD), but in bringing OUD pharmacotherapy to mainstream medicine.3,4 Likewise, the ...Administer buprenorphine and naloxone sublingual film as a single daily dose. (Strongly consider prescribing naloxone at the time buprenorphine and naloxone sublingual film is initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose.2.2

Fritz squire primerica.

How to authorize an iphone for itunes.

2020 May 7:11:411. doi: 10.3389/fpsyt.2020.00411. eCollection 2020. ... In rats that developed withdrawal signs, a drug replacement treatment was given using mitragynine, methadone, or buprenorphine and the global withdrawal score was evaluated. Results: ...Buprenorphine Hydrochloride (Sublingual) Strength. 8 mg (base) Imprint. 54 411. Color. White. Shape. Round. View details. RP b8. Buprenorphine Hydrochloride (Sublingual) …5.2 Life-Threatening Respiratory Depression. Reference ID: 4167002. Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death.Buprenorphine is an opioid medication used to treat moderate-to-severe pain and opioid dependence and withdrawal symptoms while weaning off opioids. Common side effects of buprenorphine include headache, pain, withdrawal syndrome, insomnia, infection, weakness (asthenia), back pain, sweating, nausea, vomiting, abdominal pain, constipation, and others. Buprenorphine has a high potential for ...PRO-811 was the second open-label re-treatment study conducted in patients completing 24 weeks of treatment in PRO-806 with either Probuphine, placebo, or sublingual buprenorphine. 54 Study participants (N = 85) underwent a brief induction with 12 mg to 16 mg of sublingual buprenorphine per day before four Probuphine implants were inserted in ...Quick facts about buprenorphine for treatment of chronic pain. Non-opioid medications in combination with non-pharmacologic interventions are preferred for treatment of chronic pain.1However, when treatment with opioids is indicated, buprenorphine may be preferred over full agonist opioids due to a unique mechanism of action and safety profile:2-4.This review article will explore the safety and efficacy of buprenorphine when used in subjects with hepatic and renal impairment, the elderly, and pregnant women. While manufacturer labeling for buprenorphine products may caution against their use in these populations, further examination of available data indicates that buprenorphine can be ...Buprenorphine belongs to a class of medications called opiate partial agonists. Buprenex works by changing the way the body senses pain.acute pain. This medication guide provides information about the Buprenex brand of buprenorphine injection. Sublocade is another brand of buprenorphine injection used to treat opioid addiction. Buprenex side ... ….

Buprenorphine belongs to a class of medications called opiate partial agonists. Buprenex works by changing the way the body senses pain.acute pain. This medication guide provides information about the Buprenex brand of buprenorphine injection. Sublocade is another brand of buprenorphine injection used to treat opioid addiction. Buprenex side ...Adjust dose in 2 to 4 mg increments/decrements to a level that holds patient in treatment and suppresses opioid withdrawal signs and symptoms. Target dose: 16 mg sublingually once a day; range 4 to 24 mg/day. Maximum dose: 24 mg/day; higher doses have not shown a clinical advantage. Comments:Buprenorphine is a Schedule III opioid analgesic with unique pharmacodynamic and pharmacokinetic properties that may be preferable to those of Schedule II full μ-opioid receptor agonists. The structure of buprenorphine allows for multimechanistic interactions with opioid receptors μ, δ, κ, and opioid receptor-like 1.Deaths from opioid-related overdose have remained at epidemic levels for more than a decade without a clear solution in reach. Buprenorphine is a US Food and Drug Administration-approved medication for opioid use disorder (OUD) that can be prescribed in an outpatient setting, including telehealth, and dispensed at retail pharmacies. 1 Despite this, there are some reports that patients may ...We present a case series to illustrate a new treatment paradigm utilizing front line EMS paramedic units and high dose buprenorphine to treat withdrawal symptoms with next day bridge to long term care. The three patients described are exemplary cases, meant to represent overall characteristics of the intervention prior to complete data collection.BUPRENORPHINE treats severe pain.It is prescribed when other pain medications have not worked or cannot be tolerated. It works by blocking pain signals in the brain. It belongs to a group of medications called …SUBUTEX® (Sub-u-tex) (buprenorphine) Sublingual Tablet (CIII) Keep SUBUTEX in a secure place away from children. Accidental use by a child is a medical emergency and can result in death. If a child accidentally uses SUBUTEX, get emergency help right away. Read this Medication Guide before you start taking SUBUTEX and each time you get a refill.The opioid epidemic represents a national crisis. Oxycodone is one of the most prescribed opioid medications in the United States, whereas buprenorphine is currently the most prescribed medication ... Buprenorphine 54 411, Pill Identifier results for "54 441". Search by imprint, shape, color or drug name. ... Buprenorphine Hydrochloride (Sublingual) Strength 8 mg (base) Imprint 54 411 Color White Shape Round View details. 54 412 . Codeine Sulfate Strength 60 mg Imprint 54 412 Color White Shape Round View details. 1 / 3, Buprenorphine versus tramadol. One systematic review summarized a single, non-inferiority, 12-week, open label RCT (N=135) which was rated poor to moderate quality and compared transdermal buprenorphine to tramadol in patients with osteoarthritis of the hip and/or knee. 11 The mean changes in pain scores were similar between the buprenorphine and tramadol groups., Find practitioners authorized to treat opioid dependency with buprenorphine by state. Select a state from the map or use the dropdown lists to view practitioners by city, state or zip code who previously held a DATA-2000 waiver to prescribe buprenorphine for the treatment of opioid use disorder (OUD)., Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine is a Schedule III narcotic under the Controlled Substances Act. Buprenorphine hydrochloride is a white powder, weakly acidic with limited solubility in water (17mg/mL)., Buprenorphine injection is used as a short-term treatment to relieve severe pain in people who are expected to need an opioid pain medication and who cannot be treated with other pain medications. Buprenorphine injection is in a class of medications called opiate partial agonists. It works by changing the way the body senses pain., Buprenorphine, fentanyl and morphine are examples of strong opioids used for cancer pain relief. However, strong opioids are ineffective as pain treatment in all patients and are not well-tolerated by all patients. The aim of this Cochrane review is to assess whether buprenorphine is associated with superior, inferior or equal pain relief and ..., We presented a case of buprenorphine/naloxone successfully being used to aid in cessation and subsequent abstinence from tianeptine after years of use. An additional consideration with tianeptine use is the potential for the development or re-emergence of depression and anxiety on cessation. Chronic daily use of tianeptine may represent ..., At least 2 years of Buprenorphine prescribing experience in a family medicine, internal medicine, addiction medicine, or psychiatric practice environment. Strong communication skills, ability to build an effective provider-patient relationship that fosters engagement and adherence to a collaboratively developed care plan., The transdermal application reduces the occurrence of adverse events since the plasma buprenorphine concentration remains stable. In the post-marketing surveillance study of buprenorphine use, out of a total of 13 179 patients, 520 (4%) experienced nausea and 210 (1.6%) experienced vomiting., Find practitioners authorized to treat opioid dependency with buprenorphine by state. Select a state from the map or use the dropdown lists to view practitioners by city, state or zip code who previously held a DATA-2000 waiver to prescribe buprenorphine for the treatment of opioid use disorder (OUD)., Product details on treatment with SUBOXONE Film, including available savings if eligible, and support sign-up. Search to find a doctor, nurse practitioner or physician assistant waivered to provide opioid dependence treatment in an office setting. See full safety and prescribing information., Using too much buprenorphine, or taking too much of another narcotic while using buprenorphine, may cause an overdose. If this occurs, get emergency help right away. Symptoms of an overdose include: drowsiness, extreme dizziness or weakness, irregular, fast or slow, or shallow breathing, pale or blue lips, fingernails, or skin, pinpoint pupils ..., Transdermal buprenorphine (TDB) has demonstrated effectiveness in treating a range of chronic pain conditions, including cancer pain, nociceptive pain, and neuropathic pain and has a favorable safety profile. Worldwide, clinical experience of its use is relatively limited. There is considerable misunderstanding about the pharmacology, mechanism ..., Addresses screening and assessment and offers detailed protocols for opioid addiction treatment with buprenorphine, including management of special populations. Provides consensus‐ and evidence‐based guidance on the use of buprenorphine. Addresses screening and assessment and offers detailed protocols for opioid addiction treatment …, Addresses screening and assessment and offers detailed protocols for opioid addiction treatment with buprenorphine, including management of special populations. Provides consensus‐ and evidence‐based guidance on the use of buprenorphine. Addresses screening and assessment and offers detailed protocols for opioid addiction treatment …, Core Tip: Although opioid maintenance therapy with methadone or buprenorphine is the widely accepted first line treatment in opioid use disorders (OUDs) the risk of diversion and low retention rates limit its use.While previous attempts to introduce long-acting methadone analogues have failed due to cardiac side effects in recent years, three different long-acting buprenorphine formulations ..., Buprenorphine is a Schedule III opioid with unique pharmacodynamic and pharmacokinetic properties that contribute to effective analgesia and fewer safety risks than other opioids. This review article focuses on the buccal film formulation, which is preferable to other buprenorphine formulations on the basis of bioavailability, safety and efficacy., Buprenorphine Up to 11 days Norbuprenorphine Cannabis 11-nor-9-carboxy- Single use 2 days tetrahydrocannabinol 3 times per week 2 weeks Daily use 2 to 4 weeks Very heavy use 4 to 6 weeks, 54 775 Pill - white round, 13mm . Pill with imprint 54 775 is White, Round and has been identified as Buprenorphine Hydrochloride (Sublingual) 2 mg (base). It is supplied by Hikma Pharmaceuticals USA Inc. Buprenorphine is used in the treatment of Chronic Pain; Opiate Dependence - Maintenance; Opiate Dependence - Induction; Opioid Use Disorder; Pain and belongs to the drug class Opioids ..., Buprenorphine. Buprenorphine, sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. [17] It can be used under the tongue (sublingual), in the cheek (buccal), by injection ( intravenous and subcutaneous ), as a skin patch (transdermal), or as an implant., Buprenorphine is an opioid that is available for treatment of both chronic pain and opioid use disorder. Its use for chronic pain has been hampered by various factors including complex and often misunderstood pharmacology, challenges to transition and induction to buprenorphine from other opioids, provider perceptions around the legality of ..., QUICK START GUIDE. Specifically discuss safety concerns: Understand that discontinuing buprenorphine increases risk of overdose death upon return to illicit opioid use. Know that use of alcohol or benzodiazepines with buprenorphine increases the risk of overdose and death. Understand the importance of informing providers if they become pregnant., Try to avoid very hairy areas, or trim the hairs first before applying the patch. If you find shaving easier, shave the area a few days before you apply the patch to make sure shaving does not irritate your skin. Press the patch against your skin for at least 30 seconds. Make sure it sticks well, especially the edges., Buprenorphine/naloxone is a combination opioid medication that works well to treat opioid dependence. It works best when it's used together with counseling and mental health support. The medication is available as a tablet or film that's either dissolved under your tongue or against the inside of your cheek., Butrans™: Pain indication. 5/7.5/10/15/20mcg/hr doses, and may prescribe up to two 20mcg patches concurrently. 5mcg/hr Butrans™ is equivalent to 9-13 OME/day, depending on equianalgesic calculation used. Can be used for opioid naïve patients at lowest dose. Can be started in patients without a “withdrawal day” period from short-acting ..., Buprenorphine has high affinity for but low intrinsic activity at the μ opioid receptors, and will displace morphine, methadone, and other full opioid agonists from those receptors. Full agonists ..., Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine ..., Beyond buprenorphine, methadone is the only other effective agonist treatment. However, because access to methadone is highly regulated and restricted to opioid treatment programs only, the team feels a major sense of relief to have found that buprenorphine is a safe option to use in the ED. “Only approximately 13% of individuals …, Find practitioners authorized to treat opioid dependency with buprenorphine by state. Select a state from the map or use the dropdown lists to view practitioners by city, state or zip code who previously held a DATA-2000 waiver to prescribe buprenorphine for the treatment of opioid use disorder (OUD)., Buprenorphine (pronounced 'bew-pre-nor-feen') is an opioid prescription drug. It is taken as a replacement in the treatment of heroin and other opioid dependence. Replacing a prescribed drug to treat a drug of dependence in this way is known as pharmacotherapy. As well as improving wellbeing by preventing physical withdrawal, pharmacotherapy ..., cough. feeling faint, dizzy, or lightheaded. feeling of warmth or heat. fever. flushing or redness of the skin, especially on the face and neck. headache. hoarseness. lower back or side pain. painful or difficult urination., Buprenorphine conventional ... (series of two 300-mg doses followed by four 100-mg doses or series of six 300-mg doses) were 3.21 or 6.54 ng/mL, respectively, compared with 2.91 ng/mL following stabilization on a sublingual tablet dosage of 24 mg daily. ... (base) (54 411) View all images. Drugs.com Mobile Apps. The easiest way to lookup drug ..., Suboxone (buprenorphine/naloxone) is a prescription drug used to treat opioid dependence. Learn about side effects, dosage, how it works, and more.